WO2003084518A2 - Suspension orale de microcapsules de principes actifs - Google Patents
Suspension orale de microcapsules de principes actifs Download PDFInfo
- Publication number
- WO2003084518A2 WO2003084518A2 PCT/FR2003/001096 FR0301096W WO03084518A2 WO 2003084518 A2 WO2003084518 A2 WO 2003084518A2 FR 0301096 W FR0301096 W FR 0301096W WO 03084518 A2 WO03084518 A2 WO 03084518A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microcapsules
- active principle
- suspension
- active
- suspension according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Definitions
- Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules allowing the modified release of active principle (s)
- the field of the invention is that of the modified release of pharmaceutical active ingredients, with the exclusion of amoxicillin.
- the expression "modified release” denotes indifferently a release of the active ingredient (s) starting from the contact of the dosage form with its dissolution medium (in vivo or in in vitro) or else a release of the active principle (s) starting only after a predetermined duration ranging for example from 0.5 to several hours.
- the release time of 50% of the active ingredient (s) is typically several hours, and can range from 0.5 to 30 hours, for example.
- the invention relates to liquid pharmaceutical formulations, which can be administered orally, with modified release of active principle (s) with the exception of amoxicillin.
- These formulations consist of suspensions or dispersions of microcapsules each formed by a core comprising Arnoxicillin and by a coating enveloping said core.
- the microcapsules constituting the dispersed phase of the suspension are designed, in accordance with the invention, to allow the modified release of the active principle (s) to the exclusion of amoxicillin.
- the invention relates in particular to aqueous, "multimicrocapsular" suspensions, of active principle (s) which can be administered orally, with the exception of amoxicillin, which suspensions are stable throughout the duration of the treatment and allow the modified release of the active ingredient (excluding amoxicillin).
- active principle s
- amoxicillin which suspensions are stable throughout the duration of the treatment and allow the modified release of the active ingredient (excluding amoxicillin).
- the invention also relates to a particular process for the preparation of microcapsules intended to be placed in aqueous suspension.
- Modified release oral pharmaceutical formulations of active ingredient (s) are well known. Some of these formulations consist of tablets comprising a therapeutically active core coated with various thicknesses of non-digestible materials. More recently, microcapsules or microspheres have appeared comprising a core of active principle (s) embedded in layers of different permeability or solubility. These microcapsules / microspheres are placed, for example, in gelatin capsules, so as to form galenical systems with modified release of active principle (s).
- modified release pharmaceutical forms comprising a core of coated active agent (s) are presented in solid form: tablets, capsules, microspheres, or microcapsules.
- microcapsules in dry form, mention may in particular be made of patent EP-B-0 709 087 describes a galenic system (pharmaceutical or dietetic), preferably in the form of a tablet, advantageously disintegrable, of powder or of capsule , characterized in that it comprises microcapsules, of reservoir type, containing at least one Active Drug and / or Nutritional Principle (PA), in particular chosen from antibiotics, intended for administration by the oral route, characterized:
- PA Nutritional Principle
- At least one film-forming polymer (P1) insoluble in the fluids of the tract present in an amount of 50 to 90% by weight on a dry basis relative to the total mass of the coating composition and consisting of at least one non-water-soluble derivative cellulose, ethylcellulose and / or cellulose acetate being particularly preferred;
- plasticizer present at 2 to 20% by weight on a dry basis relative to the total mass of the coating composition and consisting of at least one of the following compounds: glycerol esters, phthalates, citrates, sebacates, esters of cetyl alcohol, castor oil, salicylic acid and cutin, castor oil being particularly preferred;
- surfactant and / or lubricant present in an amount of 2 to 20% by dry weight relative to the total mass of the coating composition and chosen from anionic surfactants, preferably the alkali or alkaline earth salts of fatty acids, stearic and / or oleic acid being preferred, and / or among nonionic surfactants, preferably polyoxyethylenated sorbitan esters and / or polyoxyethylenated castor oil derivatives, and / or from lubricating agents such as stearates, preferably calcium, magnesium, aluminum or zinc, or as stearyl fumarate, preferably sodium, and or glycerol behenate; said agent possibly comprising a single or a mixture of the above products; - in that they have a particle size between 50 and 1000 microns, - in that they are designed so as to be able to remain in the small intestine for a time of at least 5 hours approximately, and thus allow the absorption of PA
- This document relates only to dry pharmaceutical forms based on microcapsules and makes no mention of oral liquid pharmaceutical forms based on microcapsules.
- the suspensions of the invention are adapted to vials provided with syringes graduated in kg already existing and therefore does not require setting to the point of a new device.
- Modified release forms hitherto little used for children are therefore now accessible thanks to the invention.
- the advantages of such forms are the reduction in the number of daily doses and the optimization of the effectiveness of the treatment between each dose (as for example for antibiotics, anti-inflammatories, cardiovascular treatments, ).
- a liquid pharmaceutical formulation with controlled release which is easy to prepare, would constitute significant progress.
- Liquid multiparticulate dosage forms are known, more specifically colloidal suspensions, which are preferred to solid forms for the active ingredients that are highly dosed or for pediatric applications, which can be administered orally.
- the active ingredient is also ionic and has a polarity opposite to that of the resin.
- the latter can be sodium polystyrene sulfonate and the coating ionic polymer is chosen from acrylic and methacrylic acid ester polymers (EUDRAGIT®).
- EUDRAGIT® acrylic and methacrylic acid ester polymers
- the resin is impregnated with an aqueous solution of the active principle.
- the resin particles impregnated with active principle are then coated with an organic solution of ionic polymer.
- the microcapsules thus obtained can be put in the form of an oral suspension (in particular example 2).
- the use of ionic resin and coating polymer limits the possibilities of application to the ionic active principles.
- US patents US-B-4,999,189 and US-B-5,186,930 relate to liquid pharmaceutical compositions comprising ionic ion exchange resin / active ingredient complexes in suspension in a liquid phase. These resin / active ingredient complex particles are coated with a first layer of pharmaceutically acceptable wax with a high melting point and with a second outer layer of a water-insoluble and pharmaceutically acceptable polymer (ethylcellulose or methylcellulose hydroxypropylmethylcellulose, hydroxyethyl- cellulose, Eudragit® ). A plasticizer such as dibutyl cebacate can be introduced into this second outer layer. The active principle is fixed by ionic bond to the ion exchange resin.
- a water-insoluble and pharmaceutically acceptable polymer ethylcellulose or methylcellulose hydroxypropylmethylcellulose, hydroxyethyl- cellulose, Eudragit® .
- a plasticizer such as dibutyl cebacate can be introduced into this second outer layer.
- the active principle is fixed by ionic bond
- the liquid phase consists of a glucose syrup with a high fructose content and by several other ingredients such as glycerin or propylene glycol.
- Patent US-B-5, 186,930 differs from the first in that it provides an amount of first layer (wax) sufficient to prevent swelling and cracking of the particles of complex resins / active ingredients.
- suspensions are prepared by saturating the aqueous phase with the active principle, before incorporating the microcapsules of active ingredient in this aqueous phase.
- the composition of the coating of the microcapsules, allowing the modified release of the active principle, is not described in these documents. However, this coating composition is decisive in ensuring the maintenance of the modified release profile of the microcapsules, after storage in the aqueous phase. It appears that the technical proposal described does not disclose the means making it possible to solve the double problem of producing a liquid suspension of a microcapsular form with modified release, without affecting the stability of the modified release profile of the active principle to the outcome of the storage of microcapsules in the liquid phase.
- European patent application EP-A-0601 508 relates to an aqueous suspension for the oral administration of naxoprene, according to a modified release profile.
- This suspension comprises coated naxoprene microgranules, suspended in a syrupy aqueous liquid phase.
- the technical problem underlying this invention is the provision of a modified release form of naxoprene, dosed at 1000 mg and administered in a single daily dose.
- the microgranules are made of naxoprene, polyvinylpyrrolidone, and lactose (90-300 ⁇ m). Their coating is made of 4 layers. The first includes: diethylcellulose / diethylphthalate / polyethylene glycol. The second is based on EUDRAGIT (meth) acrylate / (meth) acrylic copolymers. The third contains glycerol stearate / wax / fatty alcohols. And the fourth consists of an enteric coating based on cellulose acetate / phthalate. The release of naxoprene takes place in a modified manner over 24 hours.
- Example 22 of this European patent application EP-A-0601508 includes a demonstration of the stability of the release profile after 30 days of storage of the liquid suspension.
- PCT patent application WO-A-96/01628 discloses a liquid pharmaceutical formulation for oral administration, according to a modified release profile (12 hours), of an active principle consisting of moguistein.
- the goal is to provide a liquid formulation of modified release moguistein, which is easy to measure and ingest, which has a release time to avoid multiple intakes, which is stable in aqueous suspension over time, which is tasty to promote compliance and whose manufacture does not involve recourse to toxic materials such as solvents.
- the invention proposes a suspension in a slightly hydrated liquid phase (essentially based on sorbitol and glycerin), of microgranules (90-300 ⁇ m) of moguistein coated with a first hydrophilic layer consisting of cellulose acetate / phthalate and diethylphthalate; by a second hydrophobic layer comprising glycerol stearate / wax / fatty alcohols; and by a third hydrophilic layer identical to the first.
- This multilayer form is very complex to prepare and, moreover, is specific to moguistein.
- the main objective of the present invention is to provide an aqueous suspension, of microcapsules of active principle (s) with the exclusion of Pamoxicillin, for the oral administration of the latter (or these). (s) according to a modified release profile, in which the coating of the microcapsules is designed so that the release profile is not disturbed and does not depend on the maceration time of the microcapsules in the liquid phase (preferably aqueous ).
- the release of the active ingredient (s) contained in the microcapsules, in the liquid phase would be avoided throughout the storage of the suspension, while allowing modified release of the (or ) active principle (s) as soon as it enters an environment allowing release to be triggered, namely in vivo in the gastrointestinal tract and in vitro under the conditions of a dissolution test carried out just after the suspension of the microcapsules in the solvent phase (preferably aqueous), using a type II device, according to the European Pharmacopoeia 3 rd edition, in a phosphate buffer medium pH 6.8, for a volume of 900 ml, at a temperature of 37 ° C.
- Another object of the present invention is to provide an aqueous liquid suspension of microcapsules of active principle (s) (excluding Pamoxicillin) comprising a coating film formed by a single layer.
- Another objective of the present invention is to provide an aqueous liquid suspension of microcapsules of active principle (s) (excluding amoxicillin), in which the dissolved fraction resulting from the microcapsules is less than or equal to 15%, preferably 5% by weight of the total mass of active ingredients present in the microcapsules.
- active principle s
- amoxicillin active principle
- Another objective of the present invention is to provide an aqueous liquid suspension of microcapsules of active principle (s) (excluding amoxicillin) in which part of the active principle (s) ( s) is in immediate release form and the other part of the active ingredient (s) is in modified release form (microcapsules).
- Another essential objective of the present invention is to provide an aqueous suspension of microcapsules with modified release of active principles (excluding amoxicillin) making it possible to release the active principle according to a release profile which is not altered by the aging time of the suspension.
- active principles excluding amoxicillin
- Another essential objective of the present invention is to provide an aqueous suspension of microcapsules made of particles of active principle (s) (excluding amoxicillin) individually coated, and allowing the release of this (or these ) last (s) according to an extended and / or possibly delayed profile, such that the half-release time t 1/2 is between 0.5 and 30 hours.
- active principle s
- amoxicillin excluding amoxicillin
- Another objective of the present invention is to provide an oral dosage form which is liquid and made up of a large number (for example of the order of several thousand) of microcapsules, this multiplicity ensuring statistically good reproducibility of the transit kinetics of PA throughout the gastrointestinal tract, so that this results in better control of bioavailability and therefore better efficiency.
- An essential objective of the present invention is to provide a liquid, oral dosage form formed from a plurality of coated microcapsules avoiding the use of large amounts of coating agent, the mass fraction of coating agent being comparable to that of monolithic forms.
- Another essential objective of the present invention is to provide an aqueous suspension with modified release in which the active principle (s) (excluding amoxicillin) is (are) in the form of a plurality of particles individually coated to form microcapsules and allowing the mixing of several active ingredients, released according to different respective release times.
- active principle excluding amoxicillin
- Another essential objective of the present invention is to propose the use, as a means of treatment of human or veterinary diseases, of a suspension (preferably aqueous) of microcapsules constituted by particles of active principle (s) ) (excluding amoxicillin) individually coated so as to determine the modified release of the active principle (s), without the storage in this liquid form of the microcapsules in the suspension, does not affect the altered release profile.
- a suspension preferably aqueous
- microcapsules constituted by particles of active principle (s) ) (excluding amoxicillin) individually coated so as to determine the modified release of the active principle (s), without the storage in this liquid form of the microcapsules in the suspension, does not affect the altered release profile.
- Another essential objective of the present invention is to provide a medicament based on a preferably aqueous suspension of microcapsules constituted by particles of active principle (s) (excluding amoxicillin) individually coated with to determine the modified release of the active principle (s), without the storage in this liquid form of the microcapsules in the suspension having any effect on the modified release profile.
- active principle excluding amoxicillin
- the inventors had the merit of developing a multimicrocapsular galenic system in the form of a suspension, preferably aqueous, with modified release of active principle (s) excluding amoxicillin:
- microcapsules in suspension in a liquid phase (preferably aqueous) saturated in active principle (s) or saturable in active principle (s) in contact with the microcapsules, while using a quantity limited solvent (preferably water), but nevertheless sufficient for the suspension to be easily swallowed.
- a liquid phase preferably aqueous
- active principle s
- saturable in active principle s
- the invention which satisfies the objectives set out above, among others, relates to a suspension of microcapsules in an aqueous liquid phase, allowing the modified release of at least one active principle (excluding amoxicillin ) and intended to be administered orally, characterized:
- polyacrylamide and / or a poly-N ⁇ vinylamide and / or a polyN-vinyl-lactam * 3A -at least one plasticizer present in an amount of 2 to 20, preferably from 4 to 15% by dry weight relative to the total mass of the coating composition and consisting of at least one of the following compounds: esters of glycerol, phthalates, citrates, sebacates, esters of cetyl alcohol, castor oil; 4A -at least one surfactant and / or lubricant, present in an amount of 2 to 20, preferably from 4 to 15% by dry weight relative to the total mass of the coating composition and chosen from the surfactants anionic active agents, and / or from nonionic surfactants, and / or from lubricating agents; said agent possibly comprising a single or a mixture of the above products;
- ⁇ 1 B - at least one hydrophilic polymer carrying ionized groups at neutral pH, preferably chosen from cellulose derivatives;
- ⁇ 2B - at least one hydrophobic compound, different from A,
- surfactant / lubricant optionally at least one surfactant / lubricant preferably selected from the following group of products: ⁇ anionic surfactants, ⁇ and / or nonionic surfactants;
- microcapsules of active principle designates microcapsules whose core comprises (or) active principle (s) and optionally at least one excipient.
- This suspension according to the invention makes it possible to overcome the two main obstacles to the production of an aqueous suspension of microcapsules constituted by microparticles of active principles individually coated and allowing the modified release of the latter, these two obstacles being to: a) limit the fraction of active ingredients which can be released immediately from the microcapsules, to a value less than 15%, and preferably 5
- this suspension makes it possible to facilitate the oral administration of drugs whose therapeutic doses are high and this, in particular with regard to the elderly and children, the gain in terms of compliance and success of the treatment is significantly Student.
- the modified release form is particularly advantageous for the modified release form to be a plurality of microcapsules, as indicated in the preamble to the present description.
- the families A, B, C in which the constituents of the coating composition are chosen are the following:
- ⁇ triglycerides tristearin, tripalmitin, Lubritab®, Cutina HR, 7-9, ⁇ animal and vegetable fats (beeswax, camauba wax, %), ⁇ and their mixtures.
- ⁇ the non-water-soluble derivatives of cellulose, ethylcellulose and / or cellulose acetate being particularly preferred, ⁇ acrylic derivatives,
- PVA polyvinyl alcohols
- POE polyoxyethylenes
- PVP polyvinylpyrrolidones
- glycerol and its esters preferably in the following subgroup: acetylated glycerides, glycerolmonostearate, glyceryl triacetate, glycerol tributyrate, ⁇ phthalates, preferably in the following subgroup: dibutylphthalate, diethylphthalate, dimethylphthalate, diocytylphthalate,
- ⁇ citrates preferably in the following subgroup:
- acetyltributyl citrate acetyltriethyl citrate, tributyl citrate, triethyl citrate, ⁇ sebacates, preferably in the following subgroup: diethyl sebacate, dibutyl sebacate, ⁇ adipates, 10 ⁇ azelates,
- ⁇ fumarates preferably diethyl fumarate, ⁇ malates, preferably diethylmalate, 15 ⁇ oxalates, preferably diethyloxalate,
- ⁇ malonates preferably diethylmalonate, ⁇ cutin
- the alkaline or alkaline earth salts of fatty acids, stearic and / or oleic acid being preferred ⁇ polyoxyethylenated oils preferably castor oil 30 polyoxyethylene hydrogenated, polyoxyethylene-polyoxypropylene copolymers, polyoxyethylene sorbitan esters, derivatives polyoxyethylenated castor oil, stearates, preferably calcium, magnesium, aluminum or zinc, stearyl fumarates, preferably sodium, glycerol behenate, and mixtures thereof.
- the coating film consists of a single layer, the mass of which represents from 1 to 50% by weight, preferably from 5 to 40% by weight, of the total mass of the microcapsules.
- the liquid phase is aqueous, and more preferably still, it consists of at least 20% water, and better still at least 50% by weight of water.
- This suspension according to the invention advantageously comprises: - 30 to 95% by weight, preferably 60 to 85% by weight of liquid phase (advantageously water), - 5 to 70% by weight, preferably 15 to 40% by weight weight of microcapsules.
- the quantity of liquid solvent phase (preferably water) of the active principle (s) (excluding Arnoxicillin) is such that the proportion of principle (s) ( s) active (s) dissolved and coming from the microcapsules is less than or equal to 15%, preferably 5% by weight relative to the total mass of active ingredient (s) contained in the microcapsules.
- the liquid phase is at least partly, preferably completely, saturated with the active principle (s) (excluding amoxicillin) following the incorporation of the microcapsules in this liquid phase.
- the active principle (s) are saturated by means of the active principle (s) contained in the microcapsules.
- the liquid phase is at least partly, preferably completely, saturated with the active principle (s) (excluding amoxicillin) using the principle (s) active (s) not encapsulated, before the incorporation of the microcapsules in this liquid phase.
- This embodiment is particularly advantageous for the administration of amoxicillin, in that it makes it possible to combine an immediate-release fraction and a modified-release fraction.
- the microcapsules have a particle size of less than or equal to 1,000 microns, preferably between 200 and 800 microns, and more preferably still between 200 and 600 microns.
- particle size is meant in the sense of the invention, a proportion of at least 75% by weight of microcapsules with a diameter between the considered limits of the size of the screening screen.
- the amount of coating of microcapsules advantageously represents from 1 to 50%, preferably 5 to 40%, of the weight of the coated microcapsules. This advantageous characteristic is all the more to be acquired since the microcapsules, because of their small size, have a large specific surface, which accelerates the release.
- a coating film for the microcapsules which belongs to the family. A or C.
- Another means of defining the liquid suspension according to the invention may consist in reporting an in vitro release profile produced using a type II device, according to the European pharmacopoeia 3 em ⁇ edition, in a medium phosphate buffer pH 6.8, and at a temperature of 37 ° C, such that: • the proportion PI of active principle (s) released from the microcapsules during the first 15 minutes of the dissolution test is such that:
- PI ⁇ 15 preferably PI ⁇ 5
- the suspension according to the invention is characterized in that:
- the initial in vitro release profile Pfi produced just after the suspension of the microcapsules in the solvent phase (preferably aqueous), using a type II device, according to the European Pharmacopoeia 3 rd edition, in a phosphate buffer medium pH 6.8, for a volume of 900 ml, at a temperature of 37 ° C.,
- the Pf 10 in vitro release profile produced 10 days after the microcapsules have been suspended in the solvent phase (preferably aqueous), using a type II device, according to the European Pharmacopoeia 3 rd edition, in a phosphate buffer medium pH 6.8, at a temperature of 37 ° C, are similar.
- the pH of the liquid suspension according to the invention can be either acidic or neutral.
- rheology-modifying agent it may in particular be one or more "viscosifying" agents chosen from those commonly used in the pharmaceutical industry and in particular those disclosed in "Handbook of pharmaceutical excipients - 3 rd Edition, Am. Pharmaceutical Association, Arthur H KIBBE, 2000, ISBN 0917330-96-X. Europe. 0-85369-381-1".
- viscosifying agents chosen from those commonly used in the pharmaceutical industry and in particular those disclosed in "Handbook of pharmaceutical excipients - 3 rd Edition, Am. Pharmaceutical Association, Arthur H KIBBE, 2000, ISBN 0917330-96-X. Europe. 0-85369-381-1".
- - water-soluble cellulose derivatives hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, etc.
- - polyethylene glycol alginates and their derivatives
- the suspension may also be advisable to introduce into the suspension at least one agent modifying the solubility of the active principle in the liquid-solvent phase (preferably aqueous), such as for example salts, sugars, glycerol, etc.
- agent modifying the solubility of the active principle in the liquid-solvent phase preferably aqueous
- these solutes can limit the release of the active ingredient from the microcapsules by lowering the saturation concentration of the active ingredient in the aqueous phase.
- the suspension all the qualities of an oral dosage form, easy to swallow, stable and palatable, it is advantageous that it comprises at least one other additive chosen from the group comprising: surfactants, dyes, dispersing agents , preservatives, flavoring agents, flavorings, sweeteners, antioxidants and their mixtures.
- these additives include those commonly used in the pharmaceutical industry and in particular those disclosed in "Handbook of pharmaceutical excipients - 3 rd Edition, Am. Pharmaceutical Association, Arthur H KIBBE, 2000, ISBN 0917330-96 -X. Europe.
- the active principles used for the preparation of the controlled release suspensions according to the invention can be chosen from at least one of the following large varieties of active substances: antiulcer, antidiabetic, anticoagulant, antithrombic, lipid-lowering, antiarrhythmic, vasodilator, antianginal, antihypertensive , vasoprotectors, fertility promoters, inducers and inhibitors of uterine labor, contraceptives, antibiotics, antifungals, antivirals, anticancer drugs, anti-inflammatories, analgesics, antiepileptics, antiparkinsonians, neuroleptics, hypnotics, anxiolytics, psychostimulants, antimigraine, antidepressants, antitussives, antihistamines or antiallergics.
- the invention applies more particularly to pharmaceutical active principles which must be administered orally, in high doses, for example from 500 to 1000 milligrams or more and to pediatric suspensions.
- the active principle (s) is (are) chosen from the following compounds: pentoxifylline, prazosine, acyclovir, nifedipine, diltiazem, naproxen, ibuprofen, flurbiprofen, ketoprofen, fenoprofen, indomethacin, diclofenac , fentiazac, estradiol valerate, metoprolol, sulpiride, captopril, cimetidine, zidovudine, nicardipine, terfenadine, atenolol, salbutamol, carbamazepine, ranitidine, enalapril, simvastatin, fluoxetine, alprazolam, famotidine, ganciclovirone, ganciclovirone, ganciclovirone perindopril, morphine, pentazocine,, metformin, paracetamol,
- the present invention relates to a medicament characterized in that it comprises suspension of microcapsules of active principle (s) with modified release, as defined above.
- the invention also relates to a medicament, or more exactly a galenical packaging, characterized in that it comprises a kit for preparing the suspension as defined above, which kit comprising:
- microcapsules in substantially dry form containing the active principle (s) to allow saturation of the liquid phase with active principle (s), once the two solid phases have been brought into contact and liquid;
- - And / or a mixture of microcapsules in substantially dry form comprising the dose of active principle (s) just necessary for the modified release as well as a necessary and sufficient quantity of active principle (s) not coated with immediate release, to allow saturation of the liquid phase with active principle (s), once the saturation dose of active principle (s) and the liquid phase have been brought into contact;
- microencapsulation techniques accessible to those skilled in the art, the main ones of which are summarized in the article by C. DUVERNEY and JP BENOIT in "L' due Chimique", December 1986. More specifically, the technique considered is microencapsulation by film coating, leading to individualized "reservoir” systems as opposed to matrix systems.
- Figure 1 shows the initial dissolution profiles and after 10 days of storage of the suspension according to Example 1, in% dissolved (D) as a function of time (t) in hours.
- microcapsules obtained above are placed in 37 ml of phosphate buffer pH 6.8.
- the above suspension is kept for 10 days at room temperature. After 10 days, the suspension is analyzed in dissolution.
- Type 11 device according to the European Pharmacopoeia 3rd edition, phosphate buffer medium pH 6.8, volume 900 ml, temperature 37 ° C, paddle stirring 100 rpm, UV detection 252 nm.
- Step 1 Granulated 45 g of spironolactone, 25 g of PEG 40-hydrogenated castor oil and 30 g of Povidone are dissolved beforehand in a water / acetone / isopropanol mixture (5/57/38 m / m). This solution is then sprayed on 800 g of cellulose spheres (with a diameter between 300 and 500 Dm) in a Glatt GPC-G1 fluidized air bed device.
- Step 2 Coating 50 g of granules obtained previously are coated with 1.44 g of ethylcellulose, 0.16 g of castor oil, 0.64 g of poloxamer 188 and 0.96 g of povidone dissolved in an acetone mixture / isopropanol (60/40 m / m), in a miniGlatt fluidized air bed device.
- the above suspension is stored for 19 days at room temperature. After 19 days, the suspension is analyzed in dissolution.
- Type II device according to the European Pharmacopoeia 3rd edition, phosphate buffer medium pH 6.8, volume 1000 ml, temperature 37 ° C, paddle stirring 100 rpm, UV detection 240 nm.
- Metformin crystals fraction 200-500 ⁇ m are coated with 192.4 g of ethylcellulose, 26 g of castor oil, 26 g of magnesium stearate and 20.8 g of povidone® dissolved in an acetone mixture / isopropanol 60/40 m / m, in a Glatt GPC-G1 fluidized air bed apparatus.
- Product temperature 40 ° C.
- the above suspension is stored for 12 days at room temperature. After 12 days, the suspension is analyzed in dissolution.
- Type II device according to the European Pharmacopoeia 3rd edition, phosphate buffer medium pH 6.8, volume 900 ml, temperature 37 ° C, paddle shaking 100 rpm, UV detection 232 nm.
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003246792A AU2003246792B2 (en) | 2002-04-09 | 2003-04-07 | Oral suspension of active principle microcapsules |
MXPA04009968A MXPA04009968A (es) | 2002-04-09 | 2003-04-07 | Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s). |
BRPI0309142A BRPI0309142C1 (pt) | 2002-04-09 | 2003-04-07 | suspensão de microcápsulas em uma fase líquida aquosa, que permite a liberação modificada de pelo menos um princípio ativo com exclusão da amoxicilina e que é destinada a ser administrada por via oral |
JP2003581758A JP4732696B2 (ja) | 2002-04-09 | 2003-04-07 | 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 |
IL16422103A IL164221A0 (en) | 2002-04-09 | 2003-04-07 | Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim |
US10/510,643 US7906145B2 (en) | 2002-04-09 | 2003-04-07 | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
CA2480826A CA2480826C (fr) | 2002-04-09 | 2003-04-07 | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
EP03745832A EP1492511B3 (fr) | 2002-04-09 | 2003-04-07 | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
IL16422203A IL164222A0 (en) | 2002-04-09 | 2003-04-07 | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
BR122013000700A BR122013000700B8 (pt) | 2002-04-09 | 2003-04-07 | "suspensão microcápsulas em uma fase líquida aquasa" |
ES03745832T ES2320438T7 (es) | 2002-04-09 | 2003-04-07 | Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s) |
DE60325709T DE60325709D1 (de) | 2002-04-09 | 2003-04-07 | Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen |
KR1020047016079A KR101061351B1 (ko) | 2002-04-09 | 2003-04-07 | 활성 성분 마이크로캡슐의 경구 현탁액 |
IL164222A IL164222A (en) | 2002-04-09 | 2004-09-22 | Oral pharmacological formulation in the form of an aqueous suspension for the adjusted release of active ingredients |
HK05111660.1A HK1079448A1 (en) | 2002-04-09 | 2005-12-17 | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US13/014,137 US10004693B2 (en) | 2002-04-09 | 2011-01-26 | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US14/848,603 US20150374635A1 (en) | 2002-04-09 | 2015-09-09 | Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules for the modified release of active principle(s) |
US14/848,699 US9814684B2 (en) | 2002-04-09 | 2015-09-09 | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US15/625,727 US20170281558A1 (en) | 2002-04-09 | 2017-06-16 | Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules for the modified release of active principle(s). |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0204409 | 2002-04-09 | ||
FR02/04409 | 2002-04-09 | ||
FR02/10847 | 2002-09-02 | ||
FR0210847A FR2843881B1 (fr) | 2002-09-02 | 2002-09-02 | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/510,643 A-371-Of-International US7906145B2 (en) | 2002-04-09 | 2003-04-07 | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US10510643 A-371-Of-International | 2003-04-07 | ||
US13/014,137 Continuation US10004693B2 (en) | 2002-04-09 | 2011-01-26 | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003084518A2 true WO2003084518A2 (fr) | 2003-10-16 |
WO2003084518A3 WO2003084518A3 (fr) | 2004-04-01 |
Family
ID=28793279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/001096 WO2003084518A2 (fr) | 2002-04-09 | 2003-04-07 | Suspension orale de microcapsules de principes actifs |
Country Status (16)
Country | Link |
---|---|
US (5) | US7906145B2 (fr) |
EP (1) | EP1492511B3 (fr) |
JP (1) | JP4732696B2 (fr) |
KR (1) | KR101061351B1 (fr) |
CN (1) | CN100553625C (fr) |
AT (1) | ATE419840T1 (fr) |
AU (1) | AU2003246792B2 (fr) |
BR (1) | BRPI0309142C1 (fr) |
CA (1) | CA2480826C (fr) |
DE (1) | DE60325709D1 (fr) |
ES (1) | ES2320438T7 (fr) |
HK (1) | HK1079448A1 (fr) |
IL (2) | IL164222A0 (fr) |
MX (1) | MXPA04009968A (fr) |
PT (1) | PT1492511E (fr) |
WO (1) | WO2003084518A2 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099671A2 (fr) * | 2004-04-19 | 2005-10-27 | Flamel Technologies | Forme galénique orale microparticulaire pour la libération prolongée et contrôlée de principes actifs pharmaceutiques |
FR2881652A1 (fr) * | 2005-02-08 | 2006-08-11 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
WO2006087395A1 (fr) * | 2005-02-21 | 2006-08-24 | Flamel Technologies | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii |
WO2006087394A1 (fr) * | 2005-02-21 | 2006-08-24 | Flamel Technologies | Forme pharmaceutique orale de losartan |
FR2882259A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan |
FR2884145A1 (fr) * | 2005-04-06 | 2006-10-13 | Flamel Technologies Sa | Forme pharmaceutique orale de losartan |
WO2006125819A2 (fr) * | 2005-05-24 | 2006-11-30 | Flamel Technologies | Forme medicamenteuse orale, microparticulaire, anti-mesusage |
JP2008540541A (ja) * | 2005-05-10 | 2008-11-20 | ノバルティス アクチエンゲゼルシャフト | 放出制御ファムシクロビル医薬組成物 |
US8097281B2 (en) | 2005-04-08 | 2012-01-17 | Glaxosmithkline Consumer Healthcare Gmbh & Co Kg | Composition |
EP2272506A3 (fr) * | 2002-07-26 | 2013-07-10 | Flamel Technologies | Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os |
US8652523B2 (en) | 2002-07-26 | 2014-02-18 | Flamel Technologies | Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with slow solubility |
US9814684B2 (en) | 2002-04-09 | 2017-11-14 | Flamel Ireland Limited | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US11129897B2 (en) | 2016-04-22 | 2021-09-28 | Receptor Holdings, Inc. | Fast-acting plant-based medicinal compounds and nutritional supplements |
US11246852B2 (en) | 2016-12-02 | 2022-02-15 | Receptor Holdings, Inc. | Fast-acting plant-based medicinal compounds and nutritional supplements |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
FR2841140B1 (fr) * | 2002-06-24 | 2004-10-01 | Servier Lab | Microcapsules pour la liberation retardee et controlee du perindopril |
WO2007022105A2 (fr) * | 2005-08-12 | 2007-02-22 | Rubicon Research Pvt. Ltd. | Préparations pharmaceutiques stables, procédés de fabrication desdites préparations et méthodes d'emploi |
CA2645855C (fr) | 2006-03-16 | 2015-02-03 | Tris Pharma, Inc. | Formulations a liberation modifiee contenant des complexes medicament - resine echangeuse d'ions |
US20090111736A1 (en) * | 2007-10-29 | 2009-04-30 | Sri International | Orally-Absorbed Solid Dose Formulation for Vancomycin |
EP2228054A1 (fr) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Suspensions aqueuses au riluzole |
CA2782285A1 (fr) * | 2009-12-02 | 2011-06-09 | Luigi Mapelli | Microcapsules de fexofenadine et compositions les contenant |
MX2012007448A (es) * | 2009-12-22 | 2012-09-12 | Abbott Healthcare Private Ltd | Composicion farmaceutica de liberacion controlada. |
US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
US20140178479A1 (en) | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
US9254281B2 (en) * | 2011-09-12 | 2016-02-09 | Wright State University | Composition and method for the treatment of neurodegeneration |
CN102579398A (zh) * | 2011-12-31 | 2012-07-18 | 沈阳药科大学 | 一种具有掩盖药物不良口味作用的肠溶微囊及制备方法 |
CN102552163B (zh) * | 2012-01-05 | 2013-12-04 | 金陵药业股份有限公司 | 一种酒石酸美托洛尔缓释微丸及其制备方法 |
ES2717469T3 (es) | 2012-08-15 | 2019-06-21 | Tris Pharma Inc | Comprimido masticable de metilfenidato de liberación prolongada |
EP3300015B1 (fr) | 2013-03-12 | 2019-08-14 | Panacea Biomatx Inc. | Système de fabrication de formulations personnalisées pour des individus |
EP3137057B1 (fr) * | 2014-05-01 | 2020-09-09 | Sun Pharmaceutical Industries Ltd | Compositions de metformine liquides à libération prolongée |
US10258583B2 (en) | 2014-05-01 | 2019-04-16 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
US20180104197A9 (en) * | 2014-05-01 | 2018-04-19 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
EP3137060B2 (fr) | 2014-05-01 | 2023-12-20 | Sun Pharmaceutical Industries Ltd | Compositions en suspension à libération prolongée |
WO2016016845A1 (fr) | 2014-07-30 | 2016-02-04 | Sun Pharmaceutical Industries Limited | Emballage à double chambre |
US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
JP6335692B2 (ja) * | 2014-07-08 | 2018-05-30 | ライオン株式会社 | 液体経口製剤 |
WO2016025568A1 (fr) * | 2014-08-15 | 2016-02-18 | Dow Global Technologies Llc | Dispersion d'éthylcellulose et de poudre |
MA41124A (fr) * | 2014-12-05 | 2017-10-10 | Sun Pharmaceutical Ind Ltd | Compositions en suspension à libération prolongée à rétention gastrique |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
WO2017075463A1 (fr) * | 2015-10-30 | 2017-05-04 | Cmp Development Llc | Compositions aqueuses de spironolactone |
US10493083B2 (en) | 2015-10-30 | 2019-12-03 | Cmp Development Llc | Spironolactone aqueous compositions |
US10736855B2 (en) | 2016-02-25 | 2020-08-11 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
US10238803B2 (en) | 2016-05-02 | 2019-03-26 | Sun Pharmaceutical Industries Limited | Drug delivery device for pharmaceutical compositions |
US10369078B2 (en) | 2016-05-02 | 2019-08-06 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for pharmaceutical compositions |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
GB201716716D0 (en) | 2017-10-12 | 2017-11-29 | Univ Of Hertfordshire Higher Education Corporation | Method for coating particles |
EP3740189A1 (fr) | 2017-12-18 | 2020-11-25 | Tris Pharma, Inc. | Composition de poudre de médicament à libération modifiée comprenant des systèmes de formation de raft de rétention gastrique ayant une libération de médicament par impulsions de déclenchement |
WO2019126214A1 (fr) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Composition pharmaceutique comprenant des systèmes formant un radeau de rétention gastrique de ghb à libération de médicament par impulsions de déclenchement |
WO2019126215A1 (fr) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Compositions pharmaceutiques de ghb comprenant un système de formation de réseau polymère interpénétrant flottant |
WO2020011938A1 (fr) | 2018-07-11 | 2020-01-16 | Medizinische Universität Wien | Glucocorticoïdes pour le traitement topique de la gastrite auto-immune |
JP2022522270A (ja) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物 |
US20220133647A1 (en) * | 2019-03-01 | 2022-05-05 | Avadel Legacy Pharmaceuticals, Llc | Liquid guaifenesin compositions with stable extended release profiles |
BR112022004419A2 (pt) * | 2019-09-12 | 2022-05-31 | Nulixir Inc | Partículas de núcleo-casca de liberação controlada e suspensões incluindo as mesmas |
CN112370437B (zh) * | 2020-10-20 | 2022-10-21 | 好医生药业集团有限公司 | 一种阿莫西林胶囊及其制备方法 |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (289)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029884A (en) | 1971-03-18 | 1977-06-14 | Abbott Laboratories | Adenosine-5'-carboxylic acid amides |
CA1019727A (en) | 1971-03-18 | 1977-10-25 | Abbott Laboratories | Adenosine-5'-carboxylic acid amides |
US3927216A (en) | 1971-06-01 | 1975-12-16 | Icn Pharmaceuticals | 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections |
US3864483A (en) | 1972-03-22 | 1975-02-04 | Abbott Lab | Adenosine-5{40 -carboxylic acid amides |
US4351337A (en) | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US3914415A (en) | 1973-06-14 | 1975-10-21 | Abbott Lab | Adenosine-5{40 -carboxylic acid amides |
US3914414A (en) | 1973-06-14 | 1975-10-21 | Abbott Lab | Method of increasing coronary pO{HD 2 {B in mammals |
US3892769A (en) | 1973-07-20 | 1975-07-01 | Merck & Co Inc | Acetaminophen esters of aryl salicylic acids |
US3980766A (en) | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
DE2417465A1 (de) | 1974-04-10 | 1975-10-30 | Lester R Wellman | Vorrichtung zum oeffnen und wiederverschliessen eines dicht verschlossenen flexiblen behaelters |
US3966917A (en) | 1974-07-30 | 1976-06-29 | Abbott Laboratories | Platelet aggregation inhibitors |
DE2530563C2 (de) | 1975-07-09 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Analgetische Arzneimittel mit vermindertem Mißbrauchspotential |
FR2313915A1 (fr) | 1976-01-26 | 1977-01-07 | Corneille Gilbert | Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme |
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
US4308251A (en) | 1980-01-11 | 1981-12-29 | Boots Pharmaceuticals, Inc. | Controlled release formulations of orally-active medicaments |
JPS6056122B2 (ja) | 1980-05-21 | 1985-12-09 | 塩野義製薬株式会社 | 徐放性製剤 |
US4321253A (en) | 1980-08-22 | 1982-03-23 | Beatty Morgan L | Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration |
US4454309A (en) | 1980-11-12 | 1984-06-12 | Tyndale Plains-Hunter, Ltd. | Polyurethane polyene compositions |
JPS57197214A (en) | 1981-05-29 | 1982-12-03 | Tanabe Seiyaku Co Ltd | Rapid-releasing microcapsule and its preparation |
US4443549A (en) | 1981-10-19 | 1984-04-17 | Molecular Genetics, Inc. | Production of monoclonal antibodies against bacterial adhesins |
US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
US4507276A (en) | 1982-08-20 | 1985-03-26 | Bristol-Myers Company | Analgesic capsule |
US4461759A (en) | 1983-01-03 | 1984-07-24 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of veropamil |
HU187215B (en) | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
US4833905A (en) | 1983-06-03 | 1989-05-30 | Micromatic Textron Inc. | Method for splining clutch hubs with close tolerance spline bellmouth and oil seal surface roundness |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
ATE60340T1 (de) | 1984-10-19 | 1991-02-15 | Battelle Memorial Institute | Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten. |
EP0198769A3 (fr) | 1985-04-12 | 1987-09-02 | Forest Laboratories, Inc. | Compositions thérapeutiques flottantes à libération prolongée |
EP0202027A1 (fr) | 1985-04-18 | 1986-11-20 | Sumitomo Chemical Company, Limited | Composition herbicide |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
LU85943A1 (fr) | 1985-06-12 | 1987-01-13 | Galephar | Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation |
IT1185177B (it) * | 1985-07-03 | 1987-11-04 | Metalvuoto Films Spa | Dispositivo per realizzare film plastici metallizzati presentanti zone ben delimitate prive di metallizzazione |
US5002551A (en) | 1985-08-22 | 1991-03-26 | Johnson & Johnson Medical, Inc. | Method and material for prevention of surgical adhesions |
US4693896A (en) | 1985-10-07 | 1987-09-15 | Fmc Corporation | Ethylcellulose-coated, gastric-disintegrable aspirin tablet |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
CA1327010C (fr) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production |
AU591248B2 (en) | 1986-03-27 | 1989-11-30 | Kinaform Technology, Inc. | Sustained-release pharaceutical preparation |
SE8601624D0 (sv) | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
WO1987007833A1 (fr) | 1986-06-20 | 1987-12-30 | Shacknai Jonah | Medicament a avaler a liberation entretenue |
JP2876058B2 (ja) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | 薬物送達システム |
IT1200217B (it) | 1986-09-30 | 1989-01-05 | Valducci Roberto | Membrana per uso farmaceutico ed industriale |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
SE8605515D0 (sv) | 1986-12-22 | 1986-12-22 | Astra Laekemedel Ab | A liquid dosage form for oral administration of a pharmaceutically active substance |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
ES2061623T3 (es) | 1987-03-02 | 1994-12-16 | Brocades Pharma Bv | Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico. |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
US4902513A (en) * | 1987-07-31 | 1990-02-20 | Jean Carvais | Oral sustained release medicament |
US4837031A (en) | 1987-09-17 | 1989-06-06 | Mallinckrodt, Inc. | Compositions containing ibuprofen |
US4961932A (en) | 1987-10-26 | 1990-10-09 | Alza Corporation | Plurality of tiny pills in liquid dosage form |
DE3810757A1 (de) | 1988-03-30 | 1989-10-26 | Freudenberg Carl Fa | Verfahren zur herstellung einer mikroporoesen folie |
US5268182A (en) | 1988-06-24 | 1993-12-07 | Abbott Laboratories | Sustained-release drug dosage units of terazosin |
FR2634377B1 (fr) | 1988-06-30 | 1991-09-27 | Cortial | Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif |
US5028434A (en) | 1988-07-21 | 1991-07-02 | Alza Corporation | Method for administering nilvadipine for treating cardiovascular symptoms |
IT1226940B (it) * | 1988-09-16 | 1991-02-22 | Recordati Chem Pharm | Sistema terapeutico a rilascio controllato per formulazioni farmaceutiche liquide |
ATE107854T1 (de) | 1988-09-30 | 1994-07-15 | Rhone Poulenc Rorer Ltd | Pharmazeutisches granulat. |
US5186930A (en) * | 1988-11-14 | 1993-02-16 | Schering Corporation | Sustained release oral suspensions |
US4999189A (en) * | 1988-11-14 | 1991-03-12 | Schering Corporation | Sustained release oral suspensions |
IT1227899B (it) * | 1988-12-23 | 1991-05-14 | Poli Ind Chimica Spa | Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni |
CA2007181C (fr) | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Compose pharmaceutique a liberation continue |
FR2642080B1 (fr) | 1989-01-23 | 1992-10-02 | Onera (Off Nat Aerospatiale) | Polysilanes et leur procede de preparation |
US4948581A (en) | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
US5026559A (en) | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5084278A (en) | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
AU632602B2 (en) | 1989-08-02 | 1993-01-07 | John David Arnold | Method and preparation for reducing risk of myocardial infarction |
NZ233975A (en) | 1989-08-16 | 1992-06-25 | Sterling Drug Inc | Aspirin granules coated with a gastroprotectant |
IT1256651B (it) | 1992-12-11 | 1995-12-12 | Giancarlo Santus | Composizione farmaceutica a rilascio controllato in sospensione liquida |
EP0550436A1 (fr) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Microspheres de proteines et leurs procedes d'utilisation |
CA2071840C (fr) | 1989-11-06 | 1997-02-04 | Edith Mathiowitz | Mode de fabrication de microspheres proteiniques |
US5248516A (en) | 1989-12-19 | 1993-09-28 | Fmc Corporation | Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like |
GB9002495D0 (en) | 1990-02-05 | 1990-04-04 | Monsanto Europe Sa | Glyphosate compositions |
US5206030A (en) | 1990-02-26 | 1993-04-27 | Fmc Corporation | Film-forming composition and use for coating pharmaceuticals, foods and the like |
IT1246383B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
AU8219191A (en) | 1990-06-14 | 1992-01-07 | Kalmo Enterprises, Inc. | Stable aqueous drug suspensions |
SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
CA2083606C (fr) | 1990-06-20 | 2001-08-21 | Arne Elof Brandstrom | Derives de dialcoxypyridinylbenzimidazole; methode de preparation et utilisation en pharmacie |
WO1992001446A1 (fr) | 1990-07-20 | 1992-02-06 | Aps Research Limited | Formulations a liberation entretenue |
SE9002684D0 (sv) | 1990-08-17 | 1990-08-17 | Malvac Foundation C O Peter Pe | New peptides and their use |
EP0477135A1 (fr) | 1990-09-07 | 1992-03-25 | Warner-Lambert Company | Microcapsules enduites sphéroidales mâchables et méthodes de leur préparation |
GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
US5219895A (en) | 1991-01-29 | 1993-06-15 | Autogenesis Technologies, Inc. | Collagen-based adhesives and sealants and methods of preparation and use thereof |
US5431922A (en) | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
FI922107A0 (fi) | 1991-05-10 | 1992-05-08 | Faulding F H & Co Ltd | Mikrokapselkomposition och foerfarande. |
US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
ATE154241T1 (de) | 1991-10-01 | 1997-06-15 | Takeda Chemical Industries Ltd | Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5409709A (en) | 1991-11-29 | 1995-04-25 | Lion Corporation | Antipyretic analgesic preparation containing ibuprofen |
DE4200821A1 (de) * | 1992-01-15 | 1993-07-22 | Bayer Ag | Geschmacksmaskierte pharmazeutische mittel |
US5571533A (en) | 1992-02-07 | 1996-11-05 | Recordati, S.A., Chemical And Pharmaceutical Company | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide |
US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
US5286495A (en) | 1992-05-11 | 1994-02-15 | University Of Florida | Process for microencapsulating cells |
KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
IL103224A (en) | 1992-09-18 | 1998-08-16 | Teva Pharma | Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
CA2147862A1 (fr) | 1992-11-05 | 1994-05-11 | Robert E. Dempski | Dispositif de delivrance de medicaments |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
FR2704146B1 (fr) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules d'acide acétylsalicylique à libération contrôlée. |
SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
FR2708932B1 (fr) | 1993-08-10 | 1995-11-10 | Flamel Tech Sa | Procédé de préparation de polyaminoacides. |
EP0647448A1 (fr) | 1993-10-07 | 1995-04-12 | Euroceltique S.A. | Compositions pharmaceutiques administrables par voie oral à base d'opioides analgésiques à action prolongée |
GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
IT1269578B (it) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
JP2977907B2 (ja) | 1994-05-06 | 1999-11-15 | ファイザー・インコーポレーテッド | アジスロマイシンの放出調節された剤形 |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
JPH0873345A (ja) | 1994-09-05 | 1996-03-19 | Terumo Corp | 医薬製剤 |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
FR2724563A1 (fr) | 1994-09-15 | 1996-03-22 | Coletica | Utilisation de membranes collageniques comme protheses de regeneration peritoneale |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US5858398A (en) | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
GB9423588D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
KR0167613B1 (ko) | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | 사이클로스포린-함유 연질캅셀제 조성물 |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
JP2690276B2 (ja) | 1995-01-10 | 1997-12-10 | 科学技術振興事業団 | 静電結合型高分子ミセル薬物担体とその薬剤 |
FR2732218B1 (fr) | 1995-03-28 | 1997-08-01 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation |
US5750468A (en) | 1995-04-10 | 1998-05-12 | Monsanto Company | Glyphosate formulations containing etheramine surfactants |
US5674529A (en) | 1995-06-06 | 1997-10-07 | Church & Dwight Co., Inc. | Alkalinizing potassium salt controlled release preparations |
US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
GB9514285D0 (en) | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
DK0862431T3 (da) | 1995-09-07 | 2002-03-11 | Smithkline Beecham Plc | Anvendelse af pædiatrisk farmaceutisk formulering omfattende amoxycillin og clavulanat |
NZ322588A (en) | 1995-11-13 | 1999-01-28 | Pitmy Int Nv | An administration medium containing nitrous oxide for use in conjunction with analgesics, anti-inflammatories and anti-pyretics to enhance their action |
IT1276130B1 (it) | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
WO1997021436A1 (fr) | 1995-12-12 | 1997-06-19 | Merck & Co., Inc. | Nouvelle utilisation du losartan |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
US6245351B1 (en) | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
FR2746035B1 (fr) | 1996-03-15 | 1998-06-12 | Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications | |
US20030064108A1 (en) | 1996-04-23 | 2003-04-03 | Stefan Lukas | Taste masked pharmaceutical compositions |
DE19628341C2 (de) * | 1996-07-13 | 1998-09-17 | Sihl Gmbh | Aufzeichnungsmaterial für Tintenstrahlverfahren mit wäßriger Tinte und Verwendung zum Herstellen wasserfester und lichtbeständiger Aufzeichnungen auf diesem Material |
FR2752732B1 (fr) * | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
US5780055A (en) | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
AU5101798A (en) | 1996-12-04 | 1998-06-29 | Bristol-Myers Squibb Company | Method for oral administration of buspirone |
WO1998026803A1 (fr) | 1996-12-19 | 1998-06-25 | Daiichi Pharmaceutical Co., Ltd. | Composition pharmaceutique pour administration par voie orale |
FR2759083B1 (fr) | 1997-02-06 | 1999-04-30 | Dev Des Utilisations Du Collag | Materiau collagenique utile notamment pour la prevention d'adherences post-operatoires |
US5981761A (en) | 1997-03-27 | 1999-11-09 | Solutia Inc. | Crosslinked polyaspartate salts a process for their production |
US6162463A (en) | 1997-05-01 | 2000-12-19 | Dov Pharmaceutical Inc | Extended release formulation of diltiazem hydrochloride |
BR9809193A (pt) | 1997-05-30 | 2000-08-01 | Monsanto Co | Processo e composições para a promoção da eficácia biológica de substâncias quìmicas exógenas em plantas |
EP0998271B3 (fr) | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Formes de dosage de medicaments administres par voie orale a retention gastrique pour liberation lente de medicaments hautement solubles |
JP3677156B2 (ja) | 1997-09-05 | 2005-07-27 | 武田薬品工業株式会社 | 医薬 |
WO1999013864A2 (fr) | 1997-09-19 | 1999-03-25 | Shire Laboratories, Inc. | Granule de solution solide |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
FR2771291B1 (fr) | 1997-11-21 | 2000-02-25 | Ethypharm Lab Prod Ethiques | Spheroides, procede de preparation et compositions pharmaceutiques |
US6444246B1 (en) | 1997-12-16 | 2002-09-03 | Mccormick & Company, Inc. | Cake-resistant, hygroscopically sensitive materials and process for producing the same |
SE9704869D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
CA2314896C (fr) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Procede prevenant l'abus des doses orales d'opioides |
EA003101B1 (ru) | 1998-03-19 | 2002-12-26 | Бристол-Майерз Сквибб Компани | Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы |
US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
KR20010041019A (ko) | 1998-03-20 | 2001-05-15 | 요시히로 미와 | 위 및/또는 십이지장 부착성 의약 조성물 |
US6184220B1 (en) * | 1998-03-27 | 2001-02-06 | Boehringer Ingelheim Pharma Kg | Oral suspension of pharmaceutical substance |
EP1067914B1 (fr) | 1998-03-30 | 2006-02-22 | Jagotec Ag | Composition et procede de preparation de microparticules de substances insolubles dans l'eau |
US5945123A (en) | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
EP0974356B1 (fr) | 1998-07-15 | 2003-09-24 | Merck Sante | Comprimés contenant une combinaison de glibenclamide et de metformine |
US20020068365A1 (en) | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
AU4800999A (en) | 1998-07-28 | 2000-02-21 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
US6179862B1 (en) | 1998-08-14 | 2001-01-30 | Incept Llc | Methods and apparatus for in situ formation of hydrogels |
US6099862A (en) | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
WO2000018374A1 (fr) | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Liberation regulee de compositions nanoparticulaires |
JP2000128774A (ja) | 1998-10-26 | 2000-05-09 | Tanabe Seiyaku Co Ltd | 薬物を含有する球形微粒子の製法 |
JP4613275B2 (ja) | 1998-11-02 | 2011-01-12 | エラン ファーマ インターナショナル,リミティド | 多粒子改質放出組成物 |
JP2002529504A (ja) | 1998-11-12 | 2002-09-10 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | インスリン感作物質および他の抗糖尿病薬の放出修飾のための医薬組成物 |
FR2786098B1 (fr) | 1998-11-20 | 2003-05-30 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
DE19860698A1 (de) | 1998-12-30 | 2000-07-06 | Hexal Ag | Neue pharmazeutische Zusammensetzung |
DE60006362T2 (de) | 1999-02-23 | 2004-08-26 | Yuhan Corp. | Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
NZ514575A (en) | 1999-04-13 | 2004-05-28 | Beecham Pharm Pte Ltd | Novel method of treatment |
US7576131B2 (en) | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
SE9902386D0 (sv) | 1999-06-22 | 1999-06-22 | Astra Ab | New formulation |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
MXPA02000725A (es) | 1999-07-29 | 2003-07-14 | Roxane Lab Inc | Formulacion opioide de liberacion sostenida. |
US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
ATE279186T1 (de) * | 1999-08-31 | 2004-10-15 | Gruenenthal Gmbh | Retardierte darreichungsform enthaltend tramadolsaccharinat |
DE19940740A1 (de) * | 1999-08-31 | 2001-03-01 | Gruenenthal Gmbh | Pharmazeutische Salze |
ES2168043B1 (es) | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
US6264983B1 (en) | 1999-09-16 | 2001-07-24 | Rhodia, Inc. | Directly compressible, ultra fine acetaminophen compositions and process for producing same |
AR028299A1 (es) | 1999-09-17 | 2003-05-07 | Novartis Ag | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
WO2001032157A2 (fr) | 1999-11-03 | 2001-05-10 | Bristol-Myers Squibb Company | Procede utilise pour traiter le diabete |
FR2801226B1 (fr) | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation |
DE19961897A1 (de) * | 1999-12-20 | 2001-06-28 | Basf Ag | Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen |
US6248359B1 (en) | 2000-01-05 | 2001-06-19 | Laboratorios Phoenix U.S.A., Inc. | Multi-tablet oxybutynin system for treating incontinence |
US7785625B2 (en) | 2000-01-14 | 2010-08-31 | Lg Life Sciences, Limited | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
HUP0204163A2 (hu) | 2000-02-08 | 2003-04-28 | Euro-Celtique S.A. | Opioid agonistát és antagonistát tartalmazó szabályozott leadású készítmény és eljárás az előállítására |
AU2001232020A1 (en) | 2000-02-09 | 2001-08-20 | West Pharmaceutical Services Drug Delivery And Clinical Research Centre Limited | Floating drug delivery composition |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
US6951534B2 (en) | 2000-06-13 | 2005-10-04 | Acorn Cardiovascular, Inc. | Cardiac support device |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
JP2002003366A (ja) | 2000-06-23 | 2002-01-09 | Freunt Ind Co Ltd | 固形薬剤用水系コーティング剤組成物 |
AU6786001A (en) | 2000-07-05 | 2002-01-14 | Asahi Chemical Ind | Cellulose powder |
FR2811571B1 (fr) | 2000-07-11 | 2002-10-11 | Flamel Tech Sa | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif |
IT1318625B1 (it) | 2000-07-14 | 2003-08-27 | Roberto Valducci | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. |
US7074417B2 (en) | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US6499158B1 (en) | 2000-10-30 | 2002-12-31 | Steris, Inc. | Surgical table top and accessory clamp used thereon |
FR2816840B1 (fr) | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
WO2002053097A2 (fr) | 2000-12-28 | 2002-07-11 | Tap Pharmaceutical Products Inc. | Compositions pharmaceutiques d'un inhibiteur de la pompe a protons non gastro-resistant avec une combinaison de sel de carbonate et de sel de bicarbonate |
WO2002066002A2 (fr) | 2001-02-14 | 2002-08-29 | Glaxo Wellcome S.A. | Composition pharmaceutique |
DE60226012T2 (de) * | 2001-03-05 | 2009-05-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Geschmacksmaskierte pharmazeutische formulierungen |
FR2821745B1 (fr) | 2001-03-09 | 2004-07-02 | Ethypharm Lab Prod Ethiques | Granules et granules enrobes au gout masque |
BR0102252B1 (pt) | 2001-04-10 | 2013-10-22 | Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso | |
EP1385486A4 (fr) | 2001-04-18 | 2006-05-17 | Nostrum Pharmaceuticals Inc | Nouvel enrobage de composition pharmaceutique a liberation lente |
FR2825023B1 (fr) | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
GB0114532D0 (en) | 2001-06-14 | 2001-08-08 | Jagotec Ag | Novel compositions |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
CA2455420A1 (fr) | 2001-08-06 | 2003-02-20 | Euro-Celtique, S.A. | Compositions et procedes servant a empecher la surconsommation d'opioides |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
CA2456322A1 (fr) | 2001-08-06 | 2003-02-20 | Euro-Celtique, S.A. | Compositions et methodes destinees a prevenir l'abus d'opioides |
WO2003013467A1 (fr) | 2001-08-10 | 2003-02-20 | Beiersdorf Ag | Formulations cosmetiques de nettoyage basees sur une combinaison de laurethsulfate de sodium et de polyamphopolycarboxyglycinates alkyle |
US20030083286A1 (en) | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US6669955B2 (en) | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
EP1429728A1 (fr) * | 2001-08-29 | 2004-06-23 | SRL Technologies, Inc. | Preparations a liberation prolongee |
US20030050620A1 (en) | 2001-09-07 | 2003-03-13 | Isa Odidi | Combinatorial type controlled release drug delivery device |
US20030059397A1 (en) | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
US20030068276A1 (en) | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
FR2830447B1 (fr) | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
GB0124459D0 (en) | 2001-10-11 | 2001-12-05 | Novartis Ag | Organic compounds |
US20030104052A1 (en) | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US7413751B2 (en) | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20040126428A1 (en) | 2001-11-02 | 2004-07-01 | Lyn Hughes | Pharmaceutical formulation including a resinate and an aversive agent |
US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
KR20040107481A (ko) | 2002-03-18 | 2004-12-20 | 파마시아 코포레이션 | 알도스테론 수용체 길항물질 및 담즙산 격리제의 혼합물 |
FR2837100B1 (fr) | 2002-03-18 | 2004-07-23 | Flamel Tech Sa | Comprimes a bases de microcapsules a liberation modifiee |
WO2003080026A1 (fr) | 2002-03-22 | 2003-10-02 | Ranbaxy Laboratories Limited | Systeme d'administration de medicaments a liberation controlee de pravastatine |
US7790215B2 (en) | 2002-03-26 | 2010-09-07 | Purdue Pharma Lp | Sustained-release gel coated compositions |
IL164222A0 (en) | 2002-04-09 | 2005-12-18 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
IL164221A0 (en) | 2002-04-09 | 2005-12-18 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim |
US20050106249A1 (en) | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
AU2003219184A1 (en) | 2002-05-09 | 2003-11-11 | Diffucap-Chemobras Quimica E Farmaceutica, Ltda. | Novel method of preparing programmed-release compositions containing (s)-1-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-l-proline and the product thus obtained |
EP1505985A1 (fr) | 2002-05-10 | 2005-02-16 | Merck & Co., Inc. | Therapie de combinaison destinee a traiter des maladies a mediation par cyclooxygenase-2 chez des malades presentant un risque d'accident cardiovasculaire thrombotique |
WO2003101384A2 (fr) | 2002-05-31 | 2003-12-11 | Alza Corporation | Formes galeniques et compositions d'administration osmotique de diverses posologies de l'oxycodone |
FR2840614B1 (fr) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques |
CA2491572C (fr) | 2002-07-05 | 2010-03-23 | Collegium Pharmaceutical, Inc. | Compositions pharmaceutiques empechant la consommation abusive d'opioides et d'autres drogues |
NZ520149A (en) | 2002-07-12 | 2003-01-31 | Reinforced Concrete Pipes Pty | Anchoring device |
US20040208936A1 (en) | 2002-07-22 | 2004-10-21 | Roland Chorin | Novel compositions |
FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
FR2843117B1 (fr) | 2002-07-30 | 2004-10-15 | Flamel Tech Sa | Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques |
US6727839B2 (en) | 2002-08-23 | 2004-04-27 | Broadcom Corporation | High speed, low power comparator |
US7538094B2 (en) | 2002-09-19 | 2009-05-26 | Three Rivers Pharmacueticals, Llc | Composition containing ribavirin and use thereof |
CA2499994C (fr) | 2002-09-23 | 2012-07-10 | Verion, Inc. | Compositions pharmaceutiques n'induisant pas l'abus |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
DE10250084A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
US20040110781A1 (en) | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
NZ539915A (en) | 2002-12-11 | 2007-09-28 | Pfizer Prod Inc | Controlled-release of an active substance into a high fat environment |
JP2004188307A (ja) | 2002-12-11 | 2004-07-08 | Japan Atom Energy Res Inst | リン酸基を有するジルコニウム担持繊維状吸着材の合成方法、及びそれを用いたヒ素の除去 |
JP4865330B2 (ja) | 2002-12-13 | 2012-02-01 | デュレクト コーポレーション | 経口ドラッグデリバリーシステム |
EP1572164A2 (fr) | 2002-12-18 | 2005-09-14 | Pain Therapeutics, Inc. | Formes posologiques orales comprenant des agents actifs au plan therapeutique dans des noyaux a liberation lente et des revetements de capsule en gelatine a liberation immediate |
WO2004064834A1 (fr) | 2003-01-21 | 2004-08-05 | Ranbaxy Laboratories Limited | Losartan amorphe co-precipite et posologies comprenant celui-ci |
BRPI0408999A (pt) | 2003-04-04 | 2006-03-28 | Pharmacia Corp | comprimidos prensados de multiparticulados de liberação oral prolongada |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
EP2279729B1 (fr) | 2003-07-17 | 2016-08-17 | Banner Life Sciences LLC | Préparations à libération controllée |
CA2534925A1 (fr) | 2003-08-06 | 2005-02-24 | Gruenenthal Gmbh | Forme de preparation securisee contre un emploi abusif |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
NZ545159A (en) | 2003-08-13 | 2009-03-31 | Smith Howard J & Ass Pty Ltd | Method of treating viral infections |
US7470435B2 (en) | 2003-11-17 | 2008-12-30 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
FR2862536B1 (fr) | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
EP3326617A1 (fr) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Formulations de médicaments empêchant |
DE102004032103A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
AR053304A1 (es) | 2004-07-01 | 2007-05-02 | Gruenenthal Gmbh | Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion. |
WO2006035418A2 (fr) | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Produits de combinaison |
CA2581002C (fr) | 2004-10-15 | 2012-01-10 | Supernus Pharmaceuticals, Inc. | Preparations pharmaceutiques pour lesquelles le risque d'abus est reduit |
FR2878161B1 (fr) | 2004-11-23 | 2008-10-31 | Flamel Technologies Sa | Forme medicamenteuse orale, solide et concue pour eviter le mesusage |
FR2878158B1 (fr) | 2004-11-24 | 2009-01-16 | Flamel Technologies Sa | Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage |
FR2889810A1 (fr) | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
FR2881652B1 (fr) | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
US20070166378A1 (en) * | 2005-06-09 | 2007-07-19 | Flamel Technologies, Inc. | Oral ribavirin pharmaceutical compositions |
WO2006133733A1 (fr) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Forme posologique orale comportant un systeme anti-abus |
FR2892937B1 (fr) | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | Forme pharmaceutique orale microparticulaire anti-mesusage |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
FR2897267A1 (fr) | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
-
2003
- 2003-04-07 IL IL16422203A patent/IL164222A0/xx unknown
- 2003-04-07 CA CA2480826A patent/CA2480826C/fr not_active Expired - Lifetime
- 2003-04-07 BR BRPI0309142A patent/BRPI0309142C1/pt not_active IP Right Cessation
- 2003-04-07 JP JP2003581758A patent/JP4732696B2/ja not_active Expired - Lifetime
- 2003-04-07 PT PT03745832T patent/PT1492511E/pt unknown
- 2003-04-07 US US10/510,643 patent/US7906145B2/en active Active
- 2003-04-07 WO PCT/FR2003/001096 patent/WO2003084518A2/fr active Application Filing
- 2003-04-07 AT AT03745832T patent/ATE419840T1/de active
- 2003-04-07 EP EP03745832A patent/EP1492511B3/fr not_active Expired - Lifetime
- 2003-04-07 ES ES03745832T patent/ES2320438T7/es active Active
- 2003-04-07 AU AU2003246792A patent/AU2003246792B2/en not_active Expired
- 2003-04-07 DE DE60325709T patent/DE60325709D1/de not_active Expired - Lifetime
- 2003-04-07 CN CNB038105284A patent/CN100553625C/zh not_active Expired - Lifetime
- 2003-04-07 MX MXPA04009968A patent/MXPA04009968A/es active IP Right Grant
- 2003-04-07 KR KR1020047016079A patent/KR101061351B1/ko active IP Right Grant
-
2004
- 2004-09-22 IL IL164222A patent/IL164222A/en active IP Right Grant
-
2005
- 2005-12-17 HK HK05111660.1A patent/HK1079448A1/xx not_active IP Right Cessation
-
2011
- 2011-01-26 US US13/014,137 patent/US10004693B2/en not_active Expired - Lifetime
-
2015
- 2015-09-09 US US14/848,699 patent/US9814684B2/en not_active Expired - Lifetime
- 2015-09-09 US US14/848,603 patent/US20150374635A1/en not_active Abandoned
-
2017
- 2017-06-16 US US15/625,727 patent/US20170281558A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9814684B2 (en) | 2002-04-09 | 2017-11-14 | Flamel Ireland Limited | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US10004693B2 (en) | 2002-04-09 | 2018-06-26 | Flamel Ireland Limited | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
EP2272506A3 (fr) * | 2002-07-26 | 2013-07-10 | Flamel Technologies | Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os |
US8652523B2 (en) | 2002-07-26 | 2014-02-18 | Flamel Technologies | Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with slow solubility |
WO2005099671A3 (fr) * | 2004-04-19 | 2006-06-08 | Flamel Tech Sa | Forme galénique orale microparticulaire pour la libération prolongée et contrôlée de principes actifs pharmaceutiques |
WO2005099671A2 (fr) * | 2004-04-19 | 2005-10-27 | Flamel Technologies | Forme galénique orale microparticulaire pour la libération prolongée et contrôlée de principes actifs pharmaceutiques |
FR2881652A1 (fr) * | 2005-02-08 | 2006-08-11 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
JP2008529990A (ja) * | 2005-02-08 | 2008-08-07 | フラメル・テクノロジー | 誤用防止用の微小粒子状経口薬物形態 |
WO2006089843A2 (fr) * | 2005-02-08 | 2006-08-31 | Flamel Technologies | Forme medicamenteuse orale microparticulaire anti-mesusage |
WO2006089843A3 (fr) * | 2005-02-08 | 2007-03-22 | Flamel Tech Sa | Forme medicamenteuse orale microparticulaire anti-mesusage |
WO2006087395A1 (fr) * | 2005-02-21 | 2006-08-24 | Flamel Technologies | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii |
FR2882260A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii |
FR2882259A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan |
WO2006087394A1 (fr) * | 2005-02-21 | 2006-08-24 | Flamel Technologies | Forme pharmaceutique orale de losartan |
FR2884145A1 (fr) * | 2005-04-06 | 2006-10-13 | Flamel Technologies Sa | Forme pharmaceutique orale de losartan |
US8097281B2 (en) | 2005-04-08 | 2012-01-17 | Glaxosmithkline Consumer Healthcare Gmbh & Co Kg | Composition |
JP2008540541A (ja) * | 2005-05-10 | 2008-11-20 | ノバルティス アクチエンゲゼルシャフト | 放出制御ファムシクロビル医薬組成物 |
WO2006125819A3 (fr) * | 2005-05-24 | 2008-03-06 | Flamel Tech Sa | Forme medicamenteuse orale, microparticulaire, anti-mesusage |
FR2889810A1 (fr) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
WO2006125819A2 (fr) * | 2005-05-24 | 2006-11-30 | Flamel Technologies | Forme medicamenteuse orale, microparticulaire, anti-mesusage |
US11129897B2 (en) | 2016-04-22 | 2021-09-28 | Receptor Holdings, Inc. | Fast-acting plant-based medicinal compounds and nutritional supplements |
US11246852B2 (en) | 2016-12-02 | 2022-02-15 | Receptor Holdings, Inc. | Fast-acting plant-based medicinal compounds and nutritional supplements |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2480826C (fr) | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) | |
EP1492531B1 (fr) | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiée d'amoxicilline | |
EP1524968B1 (fr) | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) | |
CA2160762C (fr) | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os | |
EP1434572B1 (fr) | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques | |
CA2428782C (fr) | Medicament a base de microcapsules d'anti-hyperglycemiant a liberation prolongee et son procede de preparation | |
WO2004010984A2 (fr) | Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os | |
FR2837100A1 (fr) | Comprimes a bases de microcapsules a liberation modifiee | |
CA2608185A1 (fr) | Medicament oral a base d'inhibiteur de pompe a protons | |
CA2501294C (fr) | Spheroides, procede de preparation et compositions pharmaceutiques | |
CA2608911A1 (fr) | Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique | |
FR2843881A1 (fr) | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) | |
FR2843880A1 (fr) | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline | |
EP1850835A1 (fr) | Forme pharmaceutique orale de losartan | |
ZA200407594B (en) | Oral suspension of active principle microcapsules | |
BR122013000700B1 (pt) | "suspension microcapsules in a net stage aquasa" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1386/KOLNP/2004 Country of ref document: IN Ref document number: 01386/KOLNP/2004 Country of ref document: IN Ref document number: 2003246792 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/07594 Country of ref document: ZA Ref document number: 200407594 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2480826 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003745832 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/009968 Country of ref document: MX Ref document number: 1020047016079 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003581758 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038105284 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003745832 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047016079 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006165807 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10510643 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10510643 Country of ref document: US |